Biovica completes 510(k) submission for DiviTum®TKa to the FDA
STOCKHOLM, Sept. 25, 2020 /PRNewswire/ — Biovica, active in blood-based cancer diagnostics, today announced that the company has filed a 510(k) submission with the U.S. Food and Drug Administration (FDA). “The 510(k) submission is a major step towards bringing DiviTum®TKa to patients and…
Comments Off on Biovica completes 510(k) submission for DiviTum®TKa to the FDA